Stat News recently covered a story concerning Ram Sasisekharan and concerns he used others’ body of work as his own underlying core research work product. He became known for his use of algorithms and other software models in the pursuit of new and better antibody therapies. Now others are making claims his work is actually theirs—such as Tillman Gerngross, CEO of New Hampshire-based Adimab LCC. Gerngross makes claims in a co-authored paper, casting doubts on professor Sasisekharan. Follow the link to the Stat New source link. TrialSite News cannot be sure of the merits of these claims. We will monitor the situation, bringing transparency to the final outcome here.